<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754429</url>
  </required_header>
  <id_info>
    <org_study_id>2008_025</org_study_id>
    <secondary_id>MK0954-338</secondary_id>
    <nct_id>NCT00754429</nct_id>
  </id_info>
  <brief_title>The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)</brief_title>
  <official_title>The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <brief_summary>
    <textblock>
      To compare the effect of losartan vs amlodipine-based antihypertensive therapy on
      atherosclerotic inflammatory markers and cerebrovascular regulation in Ischemic stroke
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MCAFV and TCD for measuring cerebral autoregulatory indices at week 0, week 6, week 18 and week 30.</measure>
    <time_frame>At week 0, week 6, week 18 and week 30.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 50mg qd for 30 weeks, if blood pressure &gt; 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5 mg q.d for 30 weeks, if blood pressure &gt; 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>losartan 50mg qd for 30 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>losartan potassium</other_name>
    <other_name>COZAAR®</other_name>
    <other_name>MK0954</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>amlodipine 5 mg q.d for 30 weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient With Tia Or Ischemic Stroke (Event Has Occurred More Thaan 4 Weeks But Less
             Than 24 Weeks, And Modified Rankin'S Scale, Mrs&lt;=3) With Mild To Moderate Hypertension

          -  Patient Has No Other Active Medical Problem, Which Might Of Itself Or By This
             Treatment Significantly Affect The Patient's Blood Pressure

          -  The Blood Level Of Hscrp&gt;0.2 Ng/Dl By Two Measurements Performed Respectively One-Week
             Apart

        Exclusion Criteria:

          -  Patients With Cardiac Arrhythmia

          -  Diabetes Mellitus

          -  Patient With Other Active Inflammatory Diseases Such As Rheumatoid Disease, Fever And
             Systemic Infection Which Will Confound The Level Of Serum CRP

          -  Patients With Known Intolerance, Contraindication Or Hypersensitivity To Losartan,
             Amlodipine and Hydrochlorothiazide

          -  Patient With Myocardial Infarction Within The Recent Three Months

          -  Anatomy Abnormality Which Results In Poor Bilateral Temporal Acoustic Windows Which
             Prevent TCD Procedure

          -  Patient Who Requires Continuous Medication With Alpha Blocking Agents

          -  Concurrent Usage Of Acei

          -  Poor Mental Function Or Any Other Reason To Expect Difficulty In Meeting The
             Requirements Of The Study

          -  Concurrent Treatment With Other Lipid-Lowering Drug

          -  Childbearing Potential Women Not Undergoing Adequate Contraceptive Control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

